Literature DB >> 6727862

Mechanism of phencyclidine binding to the acetylcholine receptor from Torpedo electroplaque.

R E Oswald, M J Bamberger, J T McLaughlin.   

Abstract

The mechanism of phencyclidine binding to Torpedo acetylcholine receptor-rich membranes was investigated. The rate of [3H]phencyclidine association is 10(3)- to 10(4)-fold more rapid when phencyclidine and carbamoylcholine are added simultaneously to acetylcholine receptor-rich membranes than when phencyclidine is added to membranes previously equilibrated with carbamoylcholine or membranes in the absence of carbamoylcholine. The mechanism of binding under conditions in which the slower rate was observed was studied with thermodynamic, viscosity, and kinetic experiments. Association and dissociation rates were highly dependent on temperature with activation energies of 26-30 kcal/mole. Viscosity had no effect on the association rate but increased the dissociation rate. These studies suggest that the binding is not diffusion-controlled but rather is limited by a significant energy barrier. The association rate was determined as a function of the concentration of acetylcholine receptor-rich membranes and the concentration of phencyclidine. In the presence of carbamoylcholine, the association rate was highly dependent upon the concentration of acetylcholine receptor but virtually insensitive to the concentration of phencyclidine. In the absence of carbamoylcholine, the association rate seemed to be a hyperbolic function of both the phencyclidine and the acetylcholine receptor concentration. The minimal model capable of explaining the data is a mechanism by which phencyclidine binds to two conformations of the acetylcholine receptor, one conformation having a higher affinity and constituting a lower percentage of receptors and the other having a lower affinity and constituting a higher percentage. The data are consistent with the possibility that the high-affinity conformation is the open-channel state of the acetylcholine receptor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727862

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Regulation of nicotinic acetylcholine receptor function by adenine nucleotides.

Authors:  V A Eterović; L Li; A Palma; M G McNamee
Journal:  Cell Mol Neurobiol       Date:  1990-09       Impact factor: 5.046

2.  Determinants of phencyclidine potency on the nicotinic acetylcholine receptors from muscle and electric organ.

Authors:  V A Eterović; R Lu; A E Eakin; A D Rodríguez; P A Ferchmin
Journal:  Cell Mol Neurobiol       Date:  1999-12       Impact factor: 5.046

3.  Interaction of 18-methoxycoronaridine with nicotinic acetylcholine receptors in different conformational states.

Authors:  Hugo R Arias; Avraham Rosenberg; Dominik Feuerbach; Katarzyna M Targowska-Duda; Ryszard Maciejewski; Krzysztof Jozwiak; Ruin Moaddel; Stanley D Glick; Irving W Wainer
Journal:  Biochim Biophys Acta       Date:  2010-03-19

4.  Demonstration and affinity labeling of a stereoselective binding site for a benzomorphan opiate on acetylcholine receptor-rich membranes from Torpedo electroplaque.

Authors:  R E Oswald; N N Pennow; J T McLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

Review 5.  Phencyclidine. Physiological actions, interactions with excitatory amino acids and endogenous ligands.

Authors:  P C Contreras; J B Monahan; T H Lanthorn; L M Pullan; D A DiMaggio; G E Handelmann; N M Gray; T L O'Donohue
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

6.  Mechanisms of noncompetitive inhibition of acetylcholine-induced single-channel currents.

Authors:  R L Papke; R E Oswald
Journal:  J Gen Physiol       Date:  1989-05       Impact factor: 4.086

Review 7.  Contributions of experimental psychiatry to research on the psychosis prodrome.

Authors:  Mitja Bodatsch; Joachim Klosterkötter; Jörg Daumann
Journal:  Front Psychiatry       Date:  2013-12-17       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.